Perjeta®

DRUG2 trials

Sponsors

Mabscale, LLC, R-Pharm

Conditions

Healthy MenLocally Advanced Breast CancerMetastatic Breast Cancer

Phase 1

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Active, not recruitingNCT05825781

Mabscale, LLCHealthy Men

Start: 2023-07-20End: 2024-09-30Updated: 2024-08-16

Phase 3

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Active, not recruitingNCT07386938

R-PharmLocally Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2024-08-09End: 2027-05-28Target: 246Updated: 2026-07-14